GCS1 Antikörper (N-Term)
-
- Target Alle GCS1 (MOGS) Antikörper anzeigen
- GCS1 (MOGS) (Mannosyl-Oligosaccharide Glucosidase (MOGS))
-
Bindungsspezifität
- AA 1-30, N-Term
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser GCS1 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB)
- Aufreinigung
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- Immunogen
- This GCS1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human GCS1.
- Klon
- RB4961-4962
- Isotyp
- Ig Fraction
- Top Product
- Discover our top product MOGS Primärantikörper
-
-
- Applikationshinweise
- WB: 1:1000
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
- Haltbarkeit
- 6 months
-
- Target
- GCS1 (MOGS) (Mannosyl-Oligosaccharide Glucosidase (MOGS))
- Andere Bezeichnung
- GCS1 (MOGS Produkte)
- Hintergrund
- GCS1 cleaves the distal alpha 1,2-linked glucose residue from the Glc(3)Man(9)GlcNAc(2) oligosaccharide precursor in a highly specific manner. Defects in GCS1 are the cause of type IIb congenital disorder of glycosylation (CDGIIb). This syndrome is also known as glucosidase I deficiency and is characterized by marked generalized hypotonia and hypomotility of the neonate, dysmorphic features, including a prominent occiput, short palpebral fissures, retrognathia, high arched palate, generalized edema, and hypoplastic genitalia. Symptoms include hepatomegaly, hypoventilation, feeding problems and seizures. The clinical course is progressive and survival is at most a few months.
- Molekulargewicht
- 91918
- Gen-ID
- 7841
- NCBI Accession
- NP_001139630, NP_006293
- UniProt
- Q13724
- Pathways
- SARS-CoV-2 Protein Interaktom
-